Effect of Peripheral Blood CD4 + CD25 + Regulatory T Cell on Postoperative Immunotherapy for Patients with Renal Carcinoma

  • Zhang, Chao-Hua (Department of Urology, First People's Hospital of Baoding) ;
  • Huang, Yan (Department of Urology, First People's Hospital of Baoding)
  • Published : 2016.06.01


Objective: To investigate the effect of peripheral blood CD4 + CD25 + regulatory T cell on postoperative immunotherapy in patients with renal carcinoma. Methods: 38 patients with renal cell carcinoma were recruited, and 20 patients from the operation group purely underwent the radical nephrectomy therapy, 18 patients from the combined group successively underwent the radical nephrectomy therapy and IFN-${\alpha}$ adjuvant immunotherapy. Additionally, 12 healthy subjects were recruited in the same period of time and regarded as the control group. Flow cytometry was used to detect CD4 +, CD8 +, CD4 + CD25+ T lymphocyte subset content and the ratio of all parts in the pre-operative period, in the first post-operative week and in the third post-operative month, compare and analyze its variation trend. Results: The CD4+CD25+ T lymphocyte subset content of individual renal carcinoma patients was significantly higher than that of the control group, also increases with the progression in the tumor stage (P<0.05). The post-operative CD4 + CD25+T lymphocytes of individual operation group and combined group patients showed different degrees of increment, but the increment of the combined group was significantly lower than that of the operation group (P<0.05). For the combined group patients with less pre-operative CD4 + CD25+T lymphocytes, their levels would increase after the immunotherapy, while the pre-operative patients with more CD4 + CD25+ T lymphocytes were the opposite situation. Conclusion: The detection of peripheral blood CD4+CD25+ regulatory T lymphocyte subset can reflect the anti-tumor immune status of renal cell carcinoma patient body. It can contribute to predict the prognosis of immunotherapy and provide reference for the choice of renal carcinoma post-operative adjuvant immunotherapy.


  1. Abe H, Kamai T (2013). Rcent advances in the treatment of metastatic renal cell carcinoma. Int J Urol, 20, 944-55.
  2. Anguille S, Smits EL, Bryant C, et al (2015). Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacol Rev, 67, 731-53.
  3. Bigot P, Lebdai S, Ravaud A, et al (2013). The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies. World J Urol, 31, 1383-8.
  4. Cao J, Huang XE, Liu J, et al (2014). Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma. Asian Pac J Cancer Prev, 14, 7171-7.
  5. Chen R, Deng X, Wu H (2014). Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis. Int Immunopharmacol, 22, 451-64.
  6. Cui L, Sun YH, Chen J, et al (2015). Analysis of Prethrombotic States in Patients with Malignant Tumors. Asian Pac J Cancer Prev, 16, 5477-82.
  7. Chodon T, Koya RC, Odunsi K (2015). Active Immunotherapy of Cancer. Immunol Invest, 44, 817-36.
  8. Hinotsu S, Kawai K, Ozono S, et al (2013). Randomized controlled study of natural interferon ${\alpha}$ as adjuvant treatment for stage II or III renal cell carcinoma. Int J Clin Oncol, 18, 68-74.
  9. Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
  10. Huang XE, Yan XC, Wang L, et al (2015). Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer. Asian Pac J Cancer Prev, 16, 7867-9.
  11. Huang XE, Wang L, Ji ZQ, et al (2015). Safety of Lienal Polypeptide Injection Combined with Chemotherapy in Treating Patients with Advanced Cancer. Asian Pac J Cancer Prev, 16, 7837-41.
  12. Huang XE, Cao J, Qian ZY, et al (2014). Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Asian Pac J Cancer Prev, 15, 8495-7.
  13. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  14. Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5.
  15. Li Y, Huang XE (2015). A Pooled Analysis on Crizotinib in Treating Chinese Patients with -ALK Positive Non-smallcell Lung Cancer. Asian Pac J Cancer Prev, 16, 4797-800.
  16. Liu MY, Huang XE (2015). Effects of analgecine on oxaliplatininduced neurotoxicity in patients with gastrointestinal cancer. Asian Pac J Cancer Prev, 16, 4465-8.
  17. Liu J, Huang XE l (2014). Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation. Asian Pac J Cancer Prev, 15, 10241-4.
  18. Liu J, Huang XE (2015). Clinical application of serum tumor abnormal protein from patients with gastric cancer. Asian Pac J Cancer Prev, 16, 4041-4.
  19. Mao Q, Li L, Zhang C, et al (2015). Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer. Pak J Pharm Sci, 28, 1055-8.
  20. Schmeel FC, Schmeel LC, Gast SM, et al (2014). Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies. Int J Mol Sci, 15, 14632-48.
  21. Wang D, Zhang B, Gao H, et al (2014). Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer, 14, 251.
  22. Wang S, Wang Z (2015). Efficacy and safety of dendritic cells cocultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer. Int Immunopharmacol, 28, 22-8.
  23. Zhao X, Zhang Z, Li H, et al (2015). Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. Cancer Lett, 362, 192-8.